Neurocrine Biosciences, Inc. (NBIX) vs Takeda Pharmaceutical Co. (TAK)
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
- Takeda Pharmaceutical Co. TAK 19.67 +1.13%
Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Co. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $61.9B against $13.9B — 4.4× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.2× against 29.6×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 0.66%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 7.12%) and the higher return on invested capital (15.0% vs 2.88%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 16 and Takeda Pharmaceutical Co. on 6.
Valuation
Profitability
| Metric | NBIX | TAK | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.94% | 65.85% | 53.94% |
| Operating margin | 23.56% | 11.61% | 0.00% |
| Net margin | 20.91% | 7.12% | 0.00% |
| Free cash flow margin | 25.80% | 24.74% | 0.00% |
| Return on equity | 22.09% | 4.42% | (0.40%) |
| Return on assets | 15.26% | 2.15% | (3.32%) |
| Return on invested capital | 15.04% | 2.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack